Elsevier

Transplantation Proceedings

Volume 44, Issue 9, November 2012, Pages 2532-2534
Transplantation Proceedings

2nd congress of the Spanish transplantation society
Kidney transplantation: Candidates
Efficacy of a Hepatitis B Vaccination Schedule With Two Cycles of Four Double Doses of Conventional Vaccine and Four Doses of Adjuvanted Vaccine in Chronic Kidney Disease Patients Evaluated for Renal Transplantation

https://doi.org/10.1016/j.transproceed.2012.09.046Get rights and content

Abstract

Introduction

The response to hepatitis B (HB) vaccine remains suboptimal among chronic kidney disease patients. The aim of this study was to analyze the efficacy of a hepatitis B vaccination schedule with two 4-double doses of conventional vaccine and four doses of adjuvant vaccine in chronic kidney disease patients evaluated for renal transplantation.

Methods

In this prospective study, we recruited chronic kidney disease patients evaluated for renal transplantation to receive four 40-μg doses of hepatitis B virus vaccine (0, 1, 2 and 6 months) and another four 40 μg doses of hepatitis B virus vaccine and four 20 μg doses of adjuvant vaccine if they were nonresponders. AntiHBs titers were analyzed before every vaccine dose and 1 month after the fourth dose.

Results

One hundred fifty-five patients were enrolled in the study. The response to the vaccination increased until the seventh dose: first dose, 5.4%; second, 29.5%; third, 66.7%; fourth, 75.9%; fifth, 83.3%; sixth, 87.3%; seventh, 92.5%; and eighth, 93.8%. AntiHBs titers after the first and second vaccination with Engerix were 10 to 99 mIU/mL in the 12% and 7.7%, 100 to 999 mIU/mL in the 30.1%, and 46.2%, and 1000 mIU/mL in the 34.9% and 15.4%, respectively. Fendrix was administrated in 6.2% of the patients and 75% of them obtained a response. AntiHBc-positive patients obtained a response with one vaccination cycle in the 71.4%. The response was influenced by age and was greater in women. Adverse events were found in 11.5% of the patients (inflammation and/or local pain), which were less frequent in men (8.9% versus 16.1%) and similar for both vaccines.

Conclusion

The response to the hepatitis B vaccination with four double doses of conventional vaccine and revaccination with the same schedule and adjuvanted vaccine shows a high response rate in chronic kidney disease evaluated for renal transplantation.

Section snippets

Methods

In this prospective study, we consecutively recruited chronic kidney disease patients evaluated for renal transplantation from January 2009 to January 2012. Nonimmunized patients received four 40 μg doses of hepatitis B virus vaccine (Engerix) at 0, 1, 2 and 6 months, four 40-μg doses of hepatitis B virus vaccine (Engerix) if they were nonresponders, and four 20-μg doses of adjuvanted vaccine (Fendrix) if they remained nonresponders. AntiHBs titers were analyzed before every vaccine dose and 1

Results

One hundred fifty-five patients were enrolled in the study (Table 1).

The response to the vaccination increased until the seventh dose (first dose, 5.4%; second, 29.5%; third, 66.7%; fourth, 75.9%; fifth, 83.3%; sixth, 87.3%; seventh, 92.5%; and eighth, 93.8%) (Fig 1). AntiHBs titers after the first and second vaccination with Engerix were 10 to 99 mIU/mL in the 12% and 7.7%, 100 to 999 mIU/mL in the 30.1% and 46.2%, and 1000 mIU/mL in the 34.9% and 15.4% (mean, 469 mIU/mL and 252 mIU/mL),

Discussion

Chronic kidney disease patients have a suboptimal response to hepatitis B vaccination due to their impared immune system. Uremia induces defects in phagocytosis and T- and B-cell function. To improve vaccination response, patients should be vaccinated as soon as possible in the course of renal disease, using a 4-double dose vaccine schedule.

This study shows that chronic kidney disease patients can reach a high response rate to hepatitis B vaccination with a different revaccination schedule. In

References (8)

  • L. Finelli et al.

    National surveillance of dialysis-associated diseases in the United States, 2002

    Semin Dial

    (2005)
  • D.R. Snydman et al.

    Hemodialysis-associated hepatitis: report of an epidemic with further evidence on mechanisms of transmission

    Am J Epidemiol

    (1976)
  • M. Carl et al.

    A common-source outbreak of hepatitis B in a hemodialysis unit

    Dial Transplant

    (1983)
  • M.J. Alter et al.

    Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit

    Ann Intern Med

    (1983)
There are more references available in the full text version of this article.

Cited by (14)

  • Hepatitis B virus vaccine and chronic kidney disease. The advances

    2021, Nefrologia
    Citation Excerpt :

    Antibody persistence was greater in the HBV-AS04 than in the standard HBV vaccine group (78.4% vs. 51.4%, P = 0.023).58 The efficacy and safety of recombinant adjuvanted HBV vaccine (HBV-AS04) has been explored in additional RCTs and observational studies (Table 2).59–62 The conclusion is that HBV-AS04 provides greater immunogenicity than conventional recombinant HB vaccines.

  • Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines

    2021, Vaccine
    Citation Excerpt :

    Fendrix®, the hepatitis B vaccine formulated with the new AS04 adjuvant (MPL + aluminum salts) by GlaxoSmithKline, may provide a good alternative [19,26–28]. The vaccine is indicated for patients with renal insufficiency, especially those on hemodialysis and pre-hemodialysis aged over 15 years old [19,22,28–35]. It has been reported that revaccination with Fendrix® has a high success rate in HIV patients who do not respond to other vaccination strategies against hepatitis B [30,34–35].

  • HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population

    2020, Clinics and Research in Hepatology and Gastroenterology
    Citation Excerpt :

    Numerous approaches have been adopted to improve the immunogenicity of recombinant HBV vaccine in patients with CKD including reinforced HB vaccine schedule [7], concomitant use of immuno-modulatory agents [8,9], vaccination by ID route [10], and administration of vaccine at pre-dialysis stage [11], among others. A recombinant HB vaccine containing an improved adjuvant system (AS04) has been introduced in the market specifically for patients with CKD [12–17]; it contains as active substance 20 mcg recombinant hepatitis B surface antigen which is adjuvanted by AS04C (containing 3-0-desacyl-4′-monophosphoryl lipid A, MPL), adsorbed on aluminium phosphate and produced in Saccharomyces cerevisiae by recombinant DNA technology. MPL is a powerful stimulant of the immune system and acts through binding on the Toll-like receptor 4 on antigen-presenting cells.

  • Variables linked to hepatitis B vaccination success in non-dialyzed chronic kidney disease patients: Use of a bayesian model

    2019, Nephrologie et Therapeutique
    Citation Excerpt :

    The factors responsible for this poor outcome are ambiguous and vary according to different studies. Some studies identify factors such as age [5,6], degree of kidney failure [6–8], diabetes [9,10], male sex [11], malnutrition [12], vitamin D deficiency [10] and specific human leukocyte antigen (HLA) profiles [13]. There are contradictions in these studies, for example, the effect of renal function is not reported in one study [14] while another does not find any predictive factor of poor immune response [15].

View all citing articles on Scopus
View full text